Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP684750.RACHKUuWxDTf8SN6HR5UbfvQN5Y-B0-YPhc8aPs8Ey7mc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP684750.RACHKUuWxDTf8SN6HR5UbfvQN5Y-B0-YPhc8aPs8Ey7mc130_assertion type Assertion NP684750.RACHKUuWxDTf8SN6HR5UbfvQN5Y-B0-YPhc8aPs8Ey7mc130_head.
- NP684750.RACHKUuWxDTf8SN6HR5UbfvQN5Y-B0-YPhc8aPs8Ey7mc130_assertion description "[The decreased tumor burden was associated with decreased bone resorption (serum TRAP5b levels were decreased by 50-60% in anti-CCL2-treated animals from VCaP or PC-3 cell osseous lesions) and microvessel density was decreased by 70% in anti-CCL2-treated animals with bone lesions from VCaP cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP684750.RACHKUuWxDTf8SN6HR5UbfvQN5Y-B0-YPhc8aPs8Ey7mc130_provenance.
- NP684750.RACHKUuWxDTf8SN6HR5UbfvQN5Y-B0-YPhc8aPs8Ey7mc130_assertion evidence source_evidence_literature NP684750.RACHKUuWxDTf8SN6HR5UbfvQN5Y-B0-YPhc8aPs8Ey7mc130_provenance.
- NP684750.RACHKUuWxDTf8SN6HR5UbfvQN5Y-B0-YPhc8aPs8Ey7mc130_assertion SIO_000772 19176388 NP684750.RACHKUuWxDTf8SN6HR5UbfvQN5Y-B0-YPhc8aPs8Ey7mc130_provenance.
- NP684750.RACHKUuWxDTf8SN6HR5UbfvQN5Y-B0-YPhc8aPs8Ey7mc130_assertion wasDerivedFrom befree-20150227 NP684750.RACHKUuWxDTf8SN6HR5UbfvQN5Y-B0-YPhc8aPs8Ey7mc130_provenance.
- NP684750.RACHKUuWxDTf8SN6HR5UbfvQN5Y-B0-YPhc8aPs8Ey7mc130_assertion wasGeneratedBy ECO_0000203 NP684750.RACHKUuWxDTf8SN6HR5UbfvQN5Y-B0-YPhc8aPs8Ey7mc130_provenance.